CanSino Biologics Surges Over 5% Following Malaysian PIC/S GMP Certification for Production Facility

Stock News03-06

CanSino Biologics (06185) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.53% to HK$33.98, with a turnover of HK$23.251 million. The company announced that its production base for the self-developed ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Menhycyx® (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) Pneupycx® (PCV13i) has passed a PIC/S GMP compliance inspection by Malaysia's National Pharmaceutical Regulatory Agency (NPRA) and recently received a GMP certificate from the NPRA. The company stated that obtaining PIC/S GMP certification signifies that its production and quality management systems now meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This achievement will not only help advance the registration and launch of Menhycyx® (MCV4) and Pneupycx® (PCV13i) in Malaysia but also lays a crucial foundation for the two vaccines' entry into other PIC/S member countries and regions, providing key support for the international expansion of the company's innovative vaccines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179828349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179828349","market":"hk","top_or_hot":-1,"title":"CanSino Biologics Surges Over 5% Following Malaysian PIC/S GMP Certification for Production Facility","media":"Stock News","content":"<p>CanSino Biologics (06185) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.53% to HK$33.98, with a turnover of HK$23.251 million. The company announced that its production base for the self-developed ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Menhycyx® (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) Pneupycx® (PCV13i) has passed a PIC/S GMP compliance inspection by Malaysia's National Pharmaceutical Regulatory Agency (NPRA) and recently received a GMP certificate from the NPRA. The company stated that obtaining PIC/S GMP certification signifies that its production and quality management systems now meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This achievement will not only help advance the registration and launch of Menhycyx® (MCV4) and Pneupycx® (PCV13i) in Malaysia but also lays a crucial foundation for the two vaccines' entry into other PIC/S member countries and regions, providing key support for the international expansion of the company's innovative vaccines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Surges Over 5% Following Malaysian PIC/S GMP Certification for Production Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Surges Over 5% Following Malaysian PIC/S GMP Certification for Production Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics (06185) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.53% to HK$33.98, with a turnover of HK$23.251 million. The company announced that its production base for the self-developed ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Menhycyx® (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) Pneupycx® (PCV13i) has passed a PIC/S GMP compliance inspection by Malaysia's National Pharmaceutical Regulatory Agency (NPRA) and recently received a GMP certificate from the NPRA. The company stated that obtaining PIC/S GMP certification signifies that its production and quality management systems now meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This achievement will not only help advance the registration and launch of Menhycyx® (MCV4) and Pneupycx® (PCV13i) in Malaysia but also lays a crucial foundation for the two vaccines' entry into other PIC/S member countries and regions, providing key support for the international expansion of the company's innovative vaccines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1179828349","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179828349","pubTimestamp":1772780786,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CanSino Biologics (06185) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.53% to HK$33.98, with a turnover of HK$23.251 million. The company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK4588":"碎股","BK1161":"生物科技","06185":"康希诺生物","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","VT":"世界全股市ETF-Vanguard"},"translate_title":"马来西亚生产设施获得PIC/S GMP认证后，康希诺生物股价飙升逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"VT":1,"06185":1},"content_text":"CanSino Biologics (06185) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.53% to HK$33.98, with a turnover of HK$23.251 million. The company announced that its production base for the self-developed ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Menhycyx® (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) Pneupycx® (PCV13i) has passed a PIC/S GMP compliance inspection by Malaysia's National Pharmaceutical Regulatory Agency (NPRA) and recently received a GMP certificate from the NPRA. The company stated that obtaining PIC/S GMP certification signifies that its production and quality management systems now meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This achievement will not only help advance the registration and launch of Menhycyx® (MCV4) and Pneupycx® (PCV13i) in Malaysia but also lays a crucial foundation for the two vaccines' entry into other PIC/S member countries and regions, providing key support for the international expansion of the company's innovative vaccines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179828349","isCrawlerRequest":true}